CureVac NV Updates On Clinical Trial - Corporate Call Transcript - Thomson StreetEvents

CureVac NV Updates On Clinical Trial - Corporate Call Transcript

CureVac NV Updates On Clinical Trial - Corporate Call Transcript - Thomson StreetEvents
CureVac NV Updates On Clinical Trial - Corporate Call Transcript
Published Jun 17, 2021
14 pages (8247 words) — Published Jun 17, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CVAC.OQ conference call or presentation 17-Jun-21 12:00pm GMT

  
Brief Excerpt:

...Operator Greetings, and welcome to results of the second interim analysis of CureVac's Pivotal Phase IIb/III HERALD Study. (Operator Instructions) Please note, this conference is being recorded. At this time, I'll turn the conference over to Sarah Fakih, Head of Corporate Communications and Investor Relations. Please go ahead. Sarah Fakih ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
CureVac NV
Ticker
CVAC.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : My first one is also on the variants. In particular for Alpha strain, I think, a few other amount of vaccines have been tested specifically strain. Do you think in the final analysis, we will be able to see -- particularly on this strain, we can draw a conclusion about the efficacy so that we can compare side to side with another mRNA vaccine? That's the first one. And the second one, I think your secondary endpoint is the prevention of the larger, severe cases of hospitalization. Do you think, in the final analysis, we'll be able to see that data as part of the data package for approval? Is there -- can you also provide some color around your interaction with EMA regarding the path forward?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I guess for EMA interaction, maybe can you provide some guidance on the timing and what specific you're looking for potential approval?

Table Of Contents

CureVac NV Q3 2021 Earnings Call Summary – 2021-11-19 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Transcript – 2021-11-19 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary – 2021-10-12 – US$ 54.00 – Edited Brief of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript – 2021-10-12 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript – 2021-07-01 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 1-Jul-21 12:00pm GMT

CureVac NV Q4 2020 Earnings Call Transcript – 2021-04-15 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 15-Apr-21 2:00pm GMT

CureVac N.V. - Special Call Transcript – 2021-02-05 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 5-Feb-21 3:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "CureVac NV Updates On Clinical Trial - Corporate Call Transcript" Jun 17, 2021. Alacra Store. Apr 19, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/CureVac-NV-Updates-On-Clinical-Trial-Corporate-Call-T14893410>
  
APA:
Thomson StreetEvents. (2021). CureVac NV Updates On Clinical Trial - Corporate Call Transcript Jun 17, 2021. New York, NY: Alacra Store. Retrieved Apr 19, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/CureVac-NV-Updates-On-Clinical-Trial-Corporate-Call-T14893410>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.